Literature DB >> 25857906

Association of spontaneous bleeding and myocardial infarction with long-term mortality after percutaneous coronary intervention.

Dhruv S Kazi1, Thomas K Leong2, Tara I Chang3, Matthew D Solomon4, Mark A Hlatky5, Alan S Go6.   

Abstract

BACKGROUND: Platelet inhibition after percutaneous coronary intervention (PCI) reduces the risk of myocardial infarction (MI) but increases the risk of bleeding. MIs and bleeds during the index hospitalization for PCI are known to negatively affect long-term outcomes. The impact of spontaneous bleeding occurring after discharge on long-term mortality is unknown.
OBJECTIVES: This study sought to examine, in a real-world cohort, the association between spontaneous major bleeding or MI after PCI and long-term mortality.
METHODS: We conducted a retrospective cohort study of patients ≥30 years of age who underwent a PCI between 1996 and 2008 in an integrated healthcare delivery system. We used extended Cox regression to examine the associations of spontaneous bleeding and MI with all-cause mortality, after adjustment for time-updated demographics, comorbidities, periprocedural events, and longitudinal medication exposure.
RESULTS: Among 32,906 patients who had a PCI and survived the index hospitalization, 530 had bleeds and 991 had MIs between 7 and 365 days post-discharge. There were 4,048 deaths over a mean follow-up of 4.42 years. The crude annual death rate after a spontaneous bleed (9.5%) or MI (7.6%) was higher than among patients who experienced neither event (2.6%). Bleeding was associated with an increased rate of death (adjusted hazard ratio [HR]: 1.61, 95% confidence interval [CI]: 1.30 to 2.00), similar to that after an MI (HR: 1.91; 95% CI: 1.62 to 2.25). The association of bleeding with death remained significant after additional adjustment for the longitudinal use of antiplatelet agents.
CONCLUSIONS: Spontaneous bleeding after a PCI was independently associated with higher long-term mortality, and conveyed a risk comparable to that of an MI during follow-up. This tradeoff between efficacy and safety bolsters the argument for personalizing antiplatelet therapy after PCI on the basis of the patient's long-term risk of both thrombotic and bleeding events.
Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  antiplatelet agents; health outcomes; health services research; hemorrhage; personalized medicine

Mesh:

Year:  2015        PMID: 25857906     DOI: 10.1016/j.jacc.2015.01.047

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  17 in total

1.  Postdischarge Bleeding After Percutaneous Coronary Intervention and Subsequent Mortality and Myocardial Infarction: Insights From the HMO Research Network-Stent Registry.

Authors:  Javier A Valle; Susan Shetterly; Thomas M Maddox; P Michael Ho; Steven M Bradley; Amneet Sandhu; David Magid; Thomas T Tsai
Journal:  Circ Cardiovasc Interv       Date:  2016-06       Impact factor: 6.546

2.  Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study.

Authors:  Eric A Secemsky; Robert W Yeh; Dean J Kereiakes; Donald E Cutlip; David J Cohen; P Gabriel Steg; Christopher P Cannon; Patricia K Apruzzese; Ralph B D'Agostino; Joseph M Massaro; Laura Mauri
Journal:  JAMA Cardiol       Date:  2017-05-01       Impact factor: 14.676

3.  Academic Research Consortium High Bleeding Risk Criteria associated with 2-year bleeding events and mortality after transcatheter aortic valve replacement discharge: a Japanese Multicentre Prospective OCEAN-TAVI Registry Study.

Authors:  Kazuki Mizutani; Gaku Nakazawa; Tomohiro Yamaguchi; Mana Ogawa; Tsukasa Okai; Fumiaki Yashima; Toru Naganuma; Futoshi Yamanaka; Norio Tada; Kensuke Takagi; Masahiro Yamawaki; Hiroshi Ueno; Minoru Tabata; Shinichi Shirai; Yusuke Watanabe; Masanori Yamamoto; Kentaro Hayashida
Journal:  Eur Heart J Open       Date:  2021-11-15

4.  Predicting long-term bleeding after percutaneous coronary intervention.

Authors:  Praneet K Sharma; Adnan K Chhatriwalla; David J Cohen; Jae-Sik Jang; Paramdeep Baweja; Kensey Gosch; Philip Jones; Richard G Bach; Suzanne V Arnold; John A Spertus
Journal:  Catheter Cardiovasc Interv       Date:  2016-04-01       Impact factor: 2.692

5.  Amphiphilic macromolecule nanoassemblies suppress smooth muscle cell proliferation and platelet adhesion.

Authors:  Jennifer W Chan; Daniel R Lewis; Latrisha K Petersen; Prabhas V Moghe; Kathryn E Uhrich
Journal:  Biomaterials       Date:  2016-01-04       Impact factor: 12.479

6.  Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial.

Authors:  Marco Valgimigli; Francesco Costa; Yuliya Lokhnygina; Robert M Clare; Lars Wallentin; David J Moliterno; Paul W Armstrong; Harvey D White; Claes Held; Philip E Aylward; Frans Van de Werf; Robert A Harrington; Kenneth W Mahaffey; Pierluigi Tricoci
Journal:  Eur Heart J       Date:  2017-03-14       Impact factor: 29.983

7.  Comparison of Midterm Outcomes Associated With Aspirin and Ticagrelor vs Aspirin Monotherapy After Coronary Artery Bypass Grafting for Acute Coronary Syndrome.

Authors:  Erik Björklund; Carl Johan Malm; Susanne J Nielsen; Emma C Hansson; Hans Tygesen; Birgitta S Romlin; Andreas Martinsson; Elmir Omerovic; Aldina Pivodic; Anders Jeppsson
Journal:  JAMA Netw Open       Date:  2021-08-02

8.  Use of Chronic Oral Anticoagulation and Associated Outcomes Among Patients Undergoing Percutaneous Coronary Intervention.

Authors:  Eric A Secemsky; Neel M Butala; Uri Kartoun; Sadiqa Mahmood; Jason H Wasfy; Kevin F Kennedy; Stanley Y Shaw; Robert W Yeh
Journal:  J Am Heart Assoc       Date:  2016-10-17       Impact factor: 5.501

9.  Incidence and prognostic impact of post discharge bleeding post acute coronary syndrome within an outpatient setting: a systematic review.

Authors:  Nafiu Ismail; Kelvin P Jordan; Sunil Rao; Tim Kinnaird; Jessica Potts; Umesh T Kadam; Mamas A Mamas
Journal:  BMJ Open       Date:  2019-02-20       Impact factor: 2.692

10.  Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials.

Authors:  Eliano P Navarese; Safi U Khan; Michalina Kołodziejczak; Jacek Kubica; Sergio Buccheri; Christopher P Cannon; Paul A Gurbel; Stefano De Servi; Andrzej Budaj; Antonio Bartorelli; Daniela Trabattoni; E Magnus Ohman; Lars Wallentin; Matthew T Roe; Stefan James
Journal:  Circulation       Date:  2020-05-29       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.